PRCT: A Misunderstood Surgical Robotics Company — What Is It Actually Worth?
The market has been pricing it as "the next Intuitive Surgical," but the company has never proven it can transition from selling hardware to collecting a per-procedure toll.
Business Model
PROCEPT BioRobotics makes surgical robots for BPH (benign prostatic hyperplasia) — an enlarged prostate that squeezes the urethra and causes urinary problems. About 40 million American men are affected, resulting in roughly 300,000 resective procedures per year.
The company’s AquaBeam / HYDROS system lets a surgeon map the resection on an ultrasound image, then a robot executes the cut automatically using a high-pressure cold waterjet. The key advantages over the legacy gold standard (TURP electrosurgical resection) are a flatter learning curve for surgeons, less nerve damage to sexual function (cold water vs. thermal energy), and the ability to treat larger prostates.
The business model mirrors the razor-and-blade playbook — sell the system upfront (~$455k per unit), then monetize each procedure through a single-use disposable handpiece (~$3,500). The handpiece is physically locked to the platform: you cannot use a third-party substitute. In FY2025, consumables already accounted for 59% of total revenue and were the primary growth driver.
The flywheel: sell systems → grow installed base → drive more procedures per system → each procedure consumes one handpiece → recurring consumables revenue compounds.
Operating Snapshot
As of Q1 2026, U.S. installed base stands at 765 systems (971 globally). Annual U.S. procedures reached ~43,000 in FY2025, with Q1 2026 at ~12,200. Gross margin is 65%. U.S. TTM revenue is approximately $280M.
The company is deeply unprofitable. FY2025 net loss was $95.6M. The problem is not gross margin — it is SG&A at 74%–78% of revenue. This SG&A is not ordinary overhead. It includes the sales force, clinical specialists, surgeon proctoring (experienced surgeons supervising a new user’s first several cases), reimbursement support staff, medical conferences, and KOL network maintenance. This is market-creation spend: PRCT is not simply selling a device, it is attempting to redirect an entire surgical pathway.
Q1 2026 operating cash flow was -$38.1M. Accounts receivable and inventory together consumed over $20M in cash. Revenue is growing, but cash is not following.
Growth History: Strong but Deteriorating
Two-year revenue CAGR was nearly 50%. But when you decompose the growth, the picture changes.
U.S. installed base grew from 315 systems in FY2023 to 718 in FY2025. U.S. procedures went from 16,500 to 43,300 — nearly tripling. Revenue growth decelerated from +61% in FY2024 to +37% in FY2025 to +20% in Q1 2026.
Yet procedures per system per year went from ~70 in FY2023, to ~71 in FY2024, to ~72 in FY2025, and actually dropped to ~66 annualized in Q1 2026. Procedure volume nearly tripled, but utilization barely moved. Virtually all growth over the past two years came from placing new systems, not from each system doing more procedures.
If utilization stays stuck at 72, growth can only continue by selling systems into new hospitals. But penetration of the ~2,700 target hospitals will eventually plateau, and when it does, if utilization has not stepped up, the consumable annuity will be far weaker than the “high-margin platform” narrative implies.
Why It Ran to $99 in 2024 and Crashed to $26 in 2025
PRCT hit an all-time high of $99.45 in December 2024, implying a $5.1B market cap and roughly 15x forward P/S. The market was pricing in sustained 66% revenue growth, record-high gross margins, narrowing EBITDA losses, a new HYDROS system launch, and an FDA breakthrough device designation for prostate cancer. Every optimistic assumption was stacked.
In 2025, the narrative unraveled. Revenue growth decelerated from 66% to 20%. Utilization declined rather than improved. SG&A as a percentage of revenue rose rather than fell. Cash flow deteriorated. The CEO was replaced. The CFO established a stock sale plan. The multiple compressed from 15x to 5.4x, and the stock fell 75%. The premium paid for unproven narratives was fully unwound.
Valuation: Only Pay for What Has Been Proven
No credit for utilization stepping up (never happened). No credit for SG&A leverage (never happened). No credit for international expansion (too early). Prostate cancer treated as an option.
Utilization is assumed flat at 72. Growth comes only from new system placements, decelerating each year. Terminal FCF margin is approximately 12% — SG&A naturally matures from 78% to roughly 40% over time without requiring utilization improvement, but does not reach the 30% levels of scaled multi-product medtech companies given PRCT’s single-product, single-specialty profile. Terminal growth is roughly 5%.
P/S multiple = terminal FCF margin × terminal P/FCF = 12% × 15x = 1.8x
U.S. TTM revenue of $280M × 1.8x = $504M operating value. Add the prostate cancer option at $223M (detailed below). Add net cash of $194M ($246M cash less $52M debt). Total equity value approximately $920M, or roughly $16 per share.
The current price of $26 represents a ~60% premium to this conservative estimate. The premium is a bet on two things that have never been demonstrated: utilization stepping up and SG&A leverage materializing.
As a floor, assume growth stops tomorrow and value only the cash flow from the existing 765 installed systems: maintenance-mode revenue of $210M, 12% FCF margin, $25M steady-state FCF capitalized at 10x, plus net cash. Approximately $444M, or roughly $8 per share.
The Prostate Cancer Option
The WATER IV RP trial is testing Aquablation for localized prostate cancer, with 280 patients enrolled and primary data expected at AUA in spring 2027.
The key question is not morbidity (Aquablation almost certainly wins on that — the cold waterjet’s advantage in preserving nerves applies equally in the cancer setting). The key question is cancer control. BPH only requires symptom relief; cancer demands proof that the tumor has been adequately removed and will not recur. Aquablation is a focal ablation, not a whole-gland removal, which theoretically carries higher residual tumor risk. HIFU — the closest precedent in the focal therapy space — has been around for two decades and has never demonstrated cancer control non-inferiority to radical prostatectomy in a randomized trial. That is a cautionary data point.
Four-scenario probability tree: data insufficient (45% probability, -$30M value), niche adoption (25%, $200M), scaled adoption (20%, $800M), standard-of-care (10%, $1,800M). Undiscounted expected value is $376M; discounted to present at 10% over ~5.5 years, approximately $223M — about 15% of the current market cap. Not zero, but not the “TAM doubles” story either.
Three Things That Matter
Same-store utilization inflection. Track U.S. procedures ÷ average U.S. installed base each quarter. Currently ~66–72 procedures per system per year, with no historical quarter above 75. Two consecutive quarters breaking through 75 and trending toward 80 would mark the transition from “equipment seller” to “procedure toll collector.” If utilization is still in the low 70s three years from now, the revenue ceiling is roughly $350M.
SG&A dollar growth vs. revenue growth. This is the simplest test of operating leverage — no need to guess what is inside SG&A. Four consecutive quarters where revenue growth exceeds SG&A growth by 10+ percentage points would be the first hard evidence that terminal FCF margin can move from 12% toward 20%. As of today, not a single quarter has shown this.
WATER IV RP data (spring 2027 AUA). Only one number matters: whether the 12-month Grade Group progression rate is non-inferior to radical prostatectomy. Cancer control non-inferiority would reprice the option from $223M to $500M+. Inferiority or ambiguity zeros it out, but does not change the U.S. BPH base business valuation.
Conservative valuation ~$16. Floor ~$8. Current price $26. The market is paying for two things that have never happened.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any securities. The author may or may not hold positions in the securities discussed. All estimates, projections, and valuations are based on publicly available information and the author’s own assumptions, which may prove to be incorrect. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Readers should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. The author assumes no liability for any losses arising from reliance on the content of this article.